**Table 3a- Patients with c/pN2M0- treatment with chemotherapy**

**and radiotherapy per time periods**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | Time periods, number of patients | | | | |
|  | 2000-2003 | 2004-2007 | 2008-2011 | 2012-  2015 | 2000-2015 |
|  |  |  |  |  |  |
| All patients with Tanyc/pN2M0 | 18 | 18 | 22 | 17 | 75 |
| Neoadjuvant chemotherapy | 4 | 1 | 0 | 6 | 11 |
| Adjuvant chemotherapy | 3 | 2 | 3 | 5 | 13 |
| Neoadjuvant radiotherapy, including CRT | 1 | 1 | 1 | 0 | 3 |
| Adjuvant radiotherapy, including CRT | 0 | 2 | 1 | 3 | 6 |
| Any chemo- or radiotherpy, with curative intent1 | 6  (33%) | 5  (28%) | 5  (23%) | 10  (59%) | 26  (35%) |
| Oncological therapy only in palliative setting | 3 | 4 | 5 | 1 | 13 |
| No oncological treatment | 9 | 9 | 12 | 6 | 36 |

1some patients are included in more than one neoadjuvant/ adjuvant treatment group and can later have been treated in the palliative setting- not shown in this table.

**Table 3b- Patients with c/pN3M0- treatment with chemotherapy**

**and radiotherapy per time periods**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | Time periods, number of patients | | | | |
|  | 2000-2003 | 2004-2007 | 2008-2011 | 2012-2015 | 2000-2015 |
|  |  |  |  |  |  |
| All patients with Tanyc/pN3M0 | 32 | 21 | 35 | 48 | 136 |
| Neoadjuvant chemotherapy | 1 | 1 | 1 | 13 | 16 |
| Adjuvant chemotherapy | 5 | 4 | 8 | 9 | 26 |
| Neoadjuvant radiotherapy, including CRT | 0 | 0 | 1 | 0 | 1 |
| Adjuvant radiotherapy, including CRT | 4 | 6 | 5 | 14 | 29 |
| Any chemo- or radiotherpy, with curative intent1 | 9  (28%) | 11  (52%) | 12  (34%) | 27  (56%) | 59  (43%) |
| Oncological therapy only in palliative setting | 11 | 4 | 10 | 5 | 30 |
| No oncological treatment | 12 | 6 | 13 | 16 | 47 |

1some patients are included in more than one neoadjuvant/ adjuvant treatment group and can later have been treated in the palliative setting- not shown in this table.